Drug Profile
Mufemilast - Tianjin Hemay Biotech
Alternative Names: Hemay 005; Phosphodiesterase 4 (PDE4) inhibitors - Tianjin Hemay BiotechLatest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Tianjin Hemay Biotech
- Developer Ganzhou Hemay Pharmaceutical; Tianjin Hemay Biotech; Tianjin Hemay Pharmaceutical
- Class 2 ring heterocyclic compounds; Acetamides; Anti-inflammatories; Antipsoriatics; Ketones; Phenyl ethers; Pyrroles; Skin disorder therapies; Small molecules; Sulfones; Thiophenes
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Behcet's syndrome; Plaque psoriasis
- Phase II Ankylosing spondylitis; Atopic dermatitis; Ulcerative colitis
Most Recent Events
- 21 Feb 2024 Ganzhou Hemay Pharmaceutical completes a phase-II trial in Atopic dermatitis (In adults, In the elderly) in China (PO) (NCT05769946)
- 15 Nov 2023 Phase-III clinical trials in Behcet's syndrome in China (PO) (NCT06145893)
- 10 Nov 2023 Adverse events and efficacy data from a phase-II trial in Behcet's syndrome presented at the ACR Convergence 2023 (ACR-ARP-2023)